2020
Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy
Gandhi R, Cyktor J, Bosch R, Mar H, Laird G, Martin A, Collier A, Riddler S, Macatangay B, Rinaldo C, Eron J, Siliciano J, McMahon D, Mellors J, Hogg E, LeBlanc R, Scello C, Palm D, Gandhi M, Fletcher C, Podany A, Aweeka F, Halvas L, Dragavon J, Joseph J, Lagattuta R, Lin L, Pederson S, Robertson K, Rubin L, Smith D, Spudich S, Tsibris A. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. The Journal Of Infectious Diseases 2020, 223: 225-233. PMID: 32823274, PMCID: PMC7857155, DOI: 10.1093/infdis/jiaa532.Peer-Reviewed Original ResearchConceptsTotal HIV-1 DNAResidual plasma viremiaAntiretroviral therapyHIV-1 DNAProvirus levelsPlasma viremiaLong-term antiretroviral therapyDefective HIV-1 provirusesHIV-1 proviral DNAReplication-competent reservoirSuppressive antiretroviral therapyMarkers of inflammationReplication-competent provirusesHIV-1 provirusART initiationImmune activationHIV-1Proviral DNATime pointsInfected cellsViremiaDefective provirusesInflammationTherapyProvirus
2006
Prevalence of CXCR4 Tropism among Antiretroviral-Treated HIV-1–Infected Patients with Detectable Viremia
Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, Price RW, Spudich SS, Lampiris H, Hoh R, Leigler T, Martin JN, Deeks SG. Prevalence of CXCR4 Tropism among Antiretroviral-Treated HIV-1–Infected Patients with Detectable Viremia. The Journal Of Infectious Diseases 2006, 194: 926-930. PMID: 16960780, DOI: 10.1086/507312.Peer-Reviewed Original ResearchConceptsT-cell countsX4-tropic virusesCXCR4-tropic virusesDetectable viremiaCell countUntreated human immunodeficiency virusHIV-1-infected patientsClinic-based cohortTreatment-naive participantsT-cell depletionHuman immunodeficiency virusViral coreceptor usageCXCR4 tropismSalvage therapySignificant CD4Advanced immunodeficiencyImmunodeficiency virusCell depletionCoreceptor usageCCR5 inhibitorsLow pretreatmentViremiaCD4VirusPatients